56 Chapter 2 Supplement 2 - (continued) First author Year Country N Disease group Age (min) Age (max) Used method* Setting Stegenga [249] 2018 United States 17 Transplantation 9 18 1 Clinical care Stegenga [250] 2008 United States 3 Oncology 13 15 1 Clinical care Stegenga [251] 2009 United States 10 Oncology 13 17 1 Clinical care Stevens [252] 2006 Canada 14 Oncology 7 16 1 Clinical care Stevens [253] 1998 United States 59 Surgery 12 17 1 Clinical care Stewart [254] 2005 United States 6 Oncology 8 16 1 Intervention development Sutters [255] 2007 United States 80 Surgery 6 15 1 Clinical care Taylor [256] 2010 United Kingdom 21 Multiple disease groups 7 16 1 Clinical care Taylor [257] 2016 Australia 26 Head / brain injury 6 15 7 Intervention development Tenniglo [258] 2017 The Netherlands 11 Oncology 12 18 2 Clinical care Tercyak [259] 1998 United States 12 Diabetes NR NR 1 Clinical care Tong [260] 2013 Australia 13 Juvenile Idiopathic Arthritis 14 19 1,2 Clinical care Trace [261] 2020 United Kingdom 5 Kidney disease 6 14 1 Clinical care Travlos [262] 2016 Australia 11 Neuromuscular disorders 14 21 1 Clinical care Ullan [263] 2012 Spain 126 Multiple disease groups 14 17 4,7 Clinical care Unguru [264] 2010 United States 37 Oncology 7 19 7 Research Van Niekerk [265] 2020 South Africa 15 Burns 9 15 2 Clinical care Van Staa [266] 2010 The Netherlands 9 Multiple disease groups 15 17 1 Research Van Staa [267] 2011 The Netherlands 31 Multiple disease groups 12 19 1 Clinical care Vaz [268] 2010 Congo 8 Human Immunodeficiency Virus 8 17 1 Clinical care Vejzovic [269] 2015 Sweden 17 Gastrointestinal diseases 10 17 1 Clinical care Viklund [270] 2009 Sweden 31 Diabetes 12 17 1 Clinical care Visentin [271] 2006 Australia 10 Diabetes 15 18 1 Clinical care Wangmo [272] 2017 Switzerland 17 Oncology 9 17 1 Clinical care Weaver [273] 2015 United States 40 Oncology 12 18 1 Clinical care
RkJQdWJsaXNoZXIy MTk4NDMw